Omada Health Inc

Análisis de la acción Omada Health Inc (OMDA)

$17.630

-0.982 (-5.57%)Al cierre

Loading chart…
Máximo
18.970
Apertura
18.950
Precio medio ponderado por volumen
18.03
Volumen
808.04K
Capitalización
—
Mínimo
17.480
Importe
14.57M
EV/EBITDA, TTM
41.18

Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure.

Análisis de IA of Omada Health Inc (OMDA)

Mantener

Omada Health Inc is currently trading at $17.63, which is below the analyst price target range of $25 to $35. However, the stock has a low RSI of 25.97, indicating it is oversold, but the forward P/E ratio is very high at 136.99, suggesting that the stock may be overvalued at this time. The recent insider selling by executives, including the CEO and President, raises some concerns about short-term confidence despite the company's long-term growth potential. Therefore, it may be prudent to hold off on buying until further clarity is provided in the upcoming Q3 earnings report on November 5, 2026.

Métricas de valoración

El PER previsto actual de Omada Health Inc (OMDA) es 136.99, frente a su media de 5 años de -105.51.

PER previsto

Valor razonable
Media 5A P/E
-105.51
P/E actual
136.99
Sobrevalorada
707.05
Infravalorada
-918.06

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
101.89
EV/EBITDA actual
41.18
Sobrevalorada
477.83
Infravalorada
-274.06

Precio/ventas previsto

Valor razonable
Media 5A P/S
3.24
P/S actual
2.80
Sobrevalorada
4.31
Infravalorada
2.17

Ballenas con OMDA en cartera

A

Andreessen Horowitz LLC

+ Con en carteraOMDA

-2.12%

Rentabilidad a 3 meses

Preguntas frecuentes sobre OMDA, respondidas por Alphio AI

Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure. It operates in the Healthcare sector.

Omada Health Inc is currently trading at $17.63, which is below the analyst price target range of $25 to $35. However, the stock has a low RSI of 25.97, indicating it is oversold, but the forward P/E ratio is very high at 136.99, suggesting that the stock may be overvalued at this time. The recent insider selling by executives, including the CEO and President, raises some concerns about short-term confidence despite the company's long-term growth potential. Therefore, it may be prudent to hold off on buying until further clarity is provided in the upcoming Q3 earnings report on November 5, 2026.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar